Literature DB >> 7474675

"Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis.

R D Toto1, H C Mitchell, R D Smith, H C Lee, D McIntire, W A Pettinger.   

Abstract

Hypertensive nephrosclerosis is a progressive renal disease and the leading cause of end-stage renal disease (ESRD) in blacks in the United States. It is generally believed that hypertensive renal injury is responsible for progressive renal failure; however, it is not known whether pharmacologic lowering of blood pressure to any level prevents progression of renal disease. Accordingly, we performed a long-term prospective randomized trial to determine whether "strict" [diastolic blood pressure (DBP) 65 to 80 mm Hg] versus "conventional" (DBP 85 to 95 mm Hg) blood pressure control is associated with a slower rate of decline in glomerular filtration rate. Eighty-seven non-diabetic patients (age 25 to 73; 68 black, 58 male) with long-standing hypertension (DBP > or = 95 mm Hg), chronic renal insufficiency (GFR < or = 70 m/min/1.73 m2) and a normal urine sediment were studied. DBP was pharmacologically lowered to < or = 80 mm Hg (3 of 4 consecutive measurements at 1 to 4 weeks intervals) after which patients were randomized. DBP and GFR (renal clearance of 125I-iothalamate) were measured at baseline, at three months and every six months post-randomization. The rate of decline in GFR (GFR slope, in ml/min/1.73 m2/year), estimated by the method of maximum likelihood in a mixed effects model, was the primary outcome variable. In a secondary analysis, 50% reduction in GFR (or a doubling of serum creatinine) from baseline, ESRD and death were combined.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7474675     DOI: 10.1038/ki.1995.361

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

1.  [Remission of chronic kidney diseases. A realistic goal?].

Authors:  Gert Mayer
Journal:  Wien Klin Wochenschr       Date:  2003-07-15       Impact factor: 1.704

2.  Kidney function and systolic blood pressure new insights from cystatin C: data from the Heart and Soul Study.

Authors:  Carmen A Peralta; Mary A Whooley; Joachim H Ix; Michael G Shlipak
Journal:  Am J Hypertens       Date:  2006-09       Impact factor: 2.689

Review 3.  Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.

Authors:  William A Pettinger
Journal:  J Cardiovasc Pharmacol       Date:  2017-03       Impact factor: 3.105

Review 4.  SPRINT and the Kidney: What Have We Learned?

Authors:  Racquel Wells; Mahboob Rahman
Journal:  Curr Hypertens Rep       Date:  2018-09-14       Impact factor: 5.369

5.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

6.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

Review 7.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

8.  Rapid progression to end-stage renal disease in young hypertensive African Americans with proteinuria.

Authors:  C I Obialo; K Hewan-Lowe
Journal:  J Natl Med Assoc       Date:  1998-11       Impact factor: 1.798

9.  Regression of hypertensive nephropathy during three years of optimal blood pressure control.

Authors:  Heidi Puttinger; Afschin Soleiman; Rainer Oberbauer
Journal:  Wien Klin Wochenschr       Date:  2003-07-15       Impact factor: 1.704

Review 10.  Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.

Authors:  Wan-Chuan Tsai; Hon-Yen Wu; Yu-Sen Peng; Ju-Yeh Yang; Hung-Yuan Chen; Yen-Ling Chiu; Shih-Ping Hsu; Mei-Ju Ko; Mei-Fen Pai; Yu-Kang Tu; Kuan-Yu Hung; Kuo-Liong Chien
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.